These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 14280312)

  • 1. SEROLOGICAL RESPONSES IN MAN TO A SINGLE SMALL DOSE OF CHOLERA VACCINE WITH SPECIAL REFERENCE TO THE LACK OF INFLUENCE OF ABO BLOOD GROUP ON NATURAL ANTIBODY OR IMMUNOLOGICAL RESPONSIVENESS.
    FINKELSTEIN RA; POWELL CJ; WOODROW JC; KREVANS JR
    Bull Johns Hopkins Hosp; 1965 Mar; 116():152-60. PubMed ID: 14280312
    [No Abstract]   [Full Text] [Related]  

  • 2. SEROLOGICAL STUDIES ON CHOLERA. I. ANTIBODY LEVELS OBSERVED IN VACCINATED AND CONVALESCENT PERSONS.
    BERAN GW
    Am J Trop Med Hyg; 1964 Sep; 13():698-707. PubMed ID: 14205890
    [No Abstract]   [Full Text] [Related]  

  • 3. SEROLOGICAL STUDIES ON CHOLERA. II. ANTIBODY LEVELS OBSERVED IN EXPERIMENTALLY VACCINATED MONKEYS.
    BERAN GW
    Am J Trop Med Hyg; 1964 Sep; 13():708-15. PubMed ID: 14205891
    [No Abstract]   [Full Text] [Related]  

  • 4. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGGLUTINATING, LETHAL TOXIN AND E1 TOR HAEMOLYSIN NEUTRALIZING POTENCY OF SERA IN CHOLERA.
    FELSENFELD O; NASUNIYA N; WATANABE Y; PENA A; DALE BN
    Bull World Health Organ; 1964; 30(6):833-44. PubMed ID: 14215189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A test of antigenicity for the selection of strains for inclusion in cholera vaccines.
    Finkelstein RA; Pongpairojana S
    Bull World Health Organ; 1968; 39(2):247-59. PubMed ID: 5303406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of the serological effects of classical cholera vaccine and of purified fraction vaccine, with or without simultaneous yellow fever vaccine (author's transl)].
    Gateff C; Dodin A; Wiart J
    Ann Microbiol (Paris); 1975; 126(2):231-46. PubMed ID: 1098542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.
    Mosley WH; McCormack WM; Ahmed A; Chowdhury AK; Barui RK
    Bull World Health Organ; 1969; 40(2):187-97. PubMed ID: 5306539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological response to cholera revaccination in a semi-closed community in Calcutta.
    Sinha R; Deb BC; Ganguly R; De SP; Abou-Gareeb AH; Shrivastava DL
    Bull World Health Organ; 1970; 43(3):407-12. PubMed ID: 5312995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRELIMINARY STUDIES ON THE DEVELOPMENT OF A LIVE ORAL VACCINE FOR ANTI-CHOLERA IMMUNIZATION.
    MUKERJEE S
    Bull World Health Organ; 1963; 29(6):753-66. PubMed ID: 14107748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
    Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
    Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
    Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
    Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children.
    Brückner S; Agnandji ST; Elias J; Berberich S; Bache E; Fernandes J; Loembe MM; Hass J; Lell B; Mordmüller B; Adegnika AA; Kremsner P; Esen M
    Vaccine; 2016 Oct; 34(44):5384-5390. PubMed ID: 27642131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate.
    Mosley WH; Benenson AS; Barui R
    Bull World Health Organ; 1968; 38(3):335-46. PubMed ID: 5302923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serological response in man to an anticholera vaccine made from killed vibrios and partially purified with aluminium hydroxide].
    Soscia M; Saletti M; Ricci A; Di Gioia M
    Ann Sclavo; 1975; 17(3):257-66. PubMed ID: 1230039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective activity of cholera vaccines against E1 Tor cholera vibrios.
    PITTMAN M; FEELEY JC
    Bull World Health Organ; 1963; 28(3):379-83. PubMed ID: 13943861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.